Netflix Adds Over 8 Million Customers, Extends Lead Over Rivals
Bloomberg Businessweek
Novartis's Growth Prospects and Drug Pipeline
This chapter delves into Novartis's drop in ADRs in the U.S. despite a profit forecast raise, emphasizing their strong performance and focus on innovative medicines. Discussions include the progress and optimism around Plavicto, potential FDA approval of Kaskali, expansion plans, and strategies to navigate competition in the pharmaceutical industry. The chapter also highlights the company's long-term vision in creating innovative medicines amidst emerging trends and geopolitical factors.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
